Lundbeck Head of R&D denies allergy aspirations

Lundbeck's recently initiated recruitment of grass allergy sufferers for a phase I trial does not herald changing winds at the pharmaceutical firm – no allergy market conquest is in the cards, says Head of R&D at Lundbeck Johan Luthman.

Lundbeck's headquarters in Denmark | Photo: Lundbeck / PR

It created ripples when it was recently uncovered that pharmaceutical firm Lundbeck is on the lookout for 36 grass allergy sufferers for a phase I study.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs